Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension

Research output: Contribution to journalShort surveypeer-review


Angiotensin receptor blockers (ARBs) have gained wide-spread use in clinical medicine during the past decade. Several large, prospective and randomized multi-center trials have led us to reconsider the role of ARBs in the treatment of hypertension. Firstly, in view of the favorable safety and side effect profile of ARBs, we recommend their use in hypertensive subjects in whom ACE inhibitors are indicated but are unable to tolerate agents of this type due to intractable cough. Secondly, in light of the results of the RENAAL and IDNT studies, we consider ARBs as the drug of choice in diabetic subjects with hypertension and proteinuria (> 300 mg/L). Thirdly, we view ACE inhibitors and ARBs as equally adequate for the treatment of diabetic patients with hypertension and microalbuminuria and recommend the use of the maximal allowable doses of these drugs in such patients. Finally, older hypertensive individuals with left ventricular hypertrophy should receive either ACE inhibitors or ARBs, as these drug classes presently appear to provide better overall protection than beta blockers or calcium channel blockers in this particular subgroup of patients.

Original languageEnglish
Pages (from-to)309-311+315
Issue number4
StatePublished - 1 Apr 2003


  • ACE inhibitors
  • Angiotensin receptor blockers
  • Hypertension
  • Microalbuminuria
  • Position paper


Dive into the research topics of 'Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension'. Together they form a unique fingerprint.

Cite this